## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -0.8% below STRENGTH zone (4.0-10.0%); PEG 2.96 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.42)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Is Colgate Palmolive Offering Value as DCF Signals 36.7% Upside in 2025?**
- Source: Simply Wall Street | 20251211T184805 | Somewhat-Bullish | Relevance: 100%
- Colgate-Palmolive (CL) is explored for its investment value, with shares at $77.76 and modest returns over the past 3-5 years. While a Discounted Cash Flow model suggests a 36.7% undervaluation, implying a target price of $122.83, its Price-to-Earnings ratio of 21.55x is higher than the industry average, signaling it may be modestly overvalued by that metric. The article encourages investors to consider different "Narratives" to form their own valuation based on future assumptions.

**2. Colgate-Palmolive Company (NYSE:CL) Declares $0.52 Quarterly Dividend**
- Source: MarketBeat | 20251211T155452 | Bullish | Relevance: 100%
- Colgate-Palmolive Company (NYSE:CL) announced a quarterly dividend of $0.52 per share, payable on February 13th, with an ex-dividend date of January 21st. The company has increased its dividend for 63 consecutive years, boasts a payout ratio of approximately 53%, and analysts project its earnings will sufficiently cover future dividends. Shares traded up 0.8% to $78.39 after the company reported better-than-expected earnings of $0.91 EPS last quarter.

**3. Colgate-Palmolive (CL) Rated Outperform by RBC as Long-Term Growth Remains in Focus**
- Source: Finviz | 20251211T090758 | Bullish | Relevance: 100%
- RBC Capital upgraded Colgate-Palmolive (CL) to Outperform, maintaining an $88 price target. Despite recent stock pressure and a challenging outlook for 2026, RBC sees an encouraging setup as Colgate works towards its long-term growth goals, supported by strong brands, global presence, and a commitment to its 2030 Strategy. The company also offers a reliable dividend, having increased payouts for 62 consecutive years.

**4. Colgate-Palmolive (CL) Rated Outperform by RBC as Long-Term Growth Remains in Focus**
- Source: Insider Monkey | 20251211T023400 | Somewhat-Bullish | Relevance: 100%
- RBC Capital upgraded Colgate-Palmolive (NYSE:CL) to Outperform from Sector Perform, maintaining an $88 price target. Despite recent pressure from slower global category growth and a challenging 2026 outlook, RBC views the stock's setup as encouraging, anticipating a return to long-term growth goals. The company continues to demonstrate strong fundamentals, including healthy brands, market share, global presence, and a consistent dividend record.

**5. Colgate-Palmolive (CL) Maintains Quarterly Dividend at $0.52**
- Source: GuruFocus | 20251210T222257 | Somewhat-Bullish | Relevance: 100%
- Colgate-Palmolive (CL) has announced it will maintain its quarterly dividend at $0.52 per share, resulting in a 2.67% forward yield. The company demonstrates robust financial health with strong profitability and a solid balance sheet, despite high leverage and some insider selling. Its valuation metrics suggest the stock is trading near historical lows, potentially offering an attractive entry point for investors.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Argus Research | $0 | $0 | 0% |
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Argus Research | down | Hold |
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.07M) |
| Sells | 7 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Long-term trend broken: trading 9.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.96 signals overvaluation risk, limited margin of safety. Forward P/E 20.4x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $63.3B |
| Beta | 0.29 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.96 |
| Forward P/E | 20.4 |
| Current P/E | 21.4 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -5.5% to -0.8% (+4.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.7%) - potential reversal signal. Below SMA200 (0.91x), long-term trend not supportive. RSI neutral at 50. OFD pattern: +MLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.81% (CS: 31) | Neutral |
| RSI_14 | 50.0 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 0.910x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $78.34
- **Stop Loss:** $75.42 (3.7% risk)
- **Target:** $81.26 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 410
- **Position Value:** $32,119.40
- **Portfolio %:** 32.12%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*